Charles Schwab Investment Management Inc. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Charles Schwab Investment Management Inc. grew its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 5.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 142,763 shares of the company’s stock after purchasing an additional 7,967 shares during the period. Charles Schwab Investment Management Inc. owned about 0.27% of EyePoint Pharmaceuticals worth $1,141,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Essex Investment Management Co. LLC boosted its position in EyePoint Pharmaceuticals by 234.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 142,144 shares of the company’s stock valued at $1,136,000 after acquiring an additional 99,606 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of EyePoint Pharmaceuticals by 51.4% during the second quarter. Deerfield Management Company L.P. Series C now owns 877,790 shares of the company’s stock valued at $7,637,000 after buying an additional 298,196 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in shares of EyePoint Pharmaceuticals by 842.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 476,250 shares of the company’s stock worth $4,143,000 after buying an additional 425,717 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of EyePoint Pharmaceuticals by 112.5% during the 2nd quarter. Renaissance Technologies LLC now owns 152,800 shares of the company’s stock worth $1,329,000 after acquiring an additional 80,900 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in EyePoint Pharmaceuticals during the second quarter valued at approximately $5,488,000. 99.41% of the stock is currently owned by institutional investors.

EyePoint Pharmaceuticals Trading Up 5.4 %

Shares of NASDAQ:EYPT opened at $8.02 on Wednesday. The company has a fifty day simple moving average of $9.78 and a 200 day simple moving average of $9.14. EyePoint Pharmaceuticals, Inc. has a 12-month low of $7.21 and a 12-month high of $30.99. The firm has a market cap of $547.37 million, a PE ratio of -4.01 and a beta of 1.45.

Wall Street Analyst Weigh In

A number of research firms have issued reports on EYPT. Scotiabank initiated coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price target for the company. Chardan Capital lifted their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Jefferies Financial Group initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They set a “buy” rating and a $15.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $25.71.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.